CryoCell Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . CryoCell International
CCEL Stock  USD 3.37  0.03  0.90%   
CryoCell International's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing CryoCell International's valuation are provided below:
Gross Profit
24.5 M
Profit Margin
(0.01)
Market Capitalization
27.2 M
Enterprise Value Revenue
1.1428
Revenue
31.7 M
There are over one hundred nineteen available fundamental signals for CryoCell International, which can be analyzed over time and compared to other ratios. We recommend to validate CryoCell International's prevailing fundamental drivers against the all of the trends between 2010 and 2026. Market Cap is expected to rise to about 66.6 M this year, although Enterprise Value will most likely fall to about 90.5 M.

CryoCell International Total Revenue

18.94 Million

Check CryoCell International financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CryoCell International's main balance sheet or income statement drivers, such as Depreciation And Amortization of 625.6 K, Selling General Administrative of 11.5 M or Total Revenue of 18.9 M, as well as many indicators such as Price To Sales Ratio of 2.41, Dividend Yield of 0.0245 or Days Sales Outstanding of 79.7. CryoCell financial statements analysis is a perfect complement when working with CryoCell International Valuation or Volatility modules.
  
Build AI portfolio with CryoCell Stock
Check out the analysis of CryoCell International Correlation against competitors.
For more information on how to buy CryoCell Stock please use our How to buy in CryoCell Stock guide.

CryoCell International Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets78.1 M74.4 M41.3 M
Slightly volatile
Other Current Liabilities2.5 M5 M3.6 M
Slightly volatile
Total Current Liabilities26.1 M24.8 M15.9 M
Slightly volatile
Property Plant And Equipment Net27.4 M26.1 M9 M
Slightly volatile
Accounts Payable1.1 M2.2 M1.5 M
Slightly volatile
Cash612.8 K645.1 K3.6 M
Pretty Stable
Non Current Assets Total62.9 M59.9 M28.7 M
Slightly volatile
Non Currrent Assets Other7 M6.6 M4.6 M
Slightly volatile
Cash And Short Term Investments5.4 M4 M4.6 M
Pretty Stable
Net Receivables8.8 M8.4 M5.4 M
Slightly volatile
Common Stock Shares Outstanding7.8 M7.4 M8.6 M
Slightly volatile
Liabilities And Stockholders Equity78.1 M74.4 M41.3 M
Slightly volatile
Non Current Liabilities Total68 M64.7 M33.7 M
Slightly volatile
Other Stockholder Equity21.8 M22.3 M19.4 M
Very volatile
Total Liabilities94.1 M89.6 M49.6 M
Slightly volatile
Total Current Assets10.6 M14.4 M12.3 M
Slightly volatile
Intangible Assets2.1 M1.1 M2.5 M
Slightly volatile
Short and Long Term Debt Total11.1 M11.6 M7.5 M
Slightly volatile
Other Current Assets1.1 M1.3 M1.1 M
Pretty Stable
Short Term Debt5 M4.7 M2.3 M
Slightly volatile
Short Term Investments2.8 M2.6 M1.1 M
Slightly volatile
Common Stock135.8 K171 K134.7 K
Slightly volatile
Other Liabilities45.9 M43.7 M25.9 M
Slightly volatile
Other Assets28.6 M27.2 M15.6 M
Slightly volatile
Long Term Debt5.5 M9.6 M5.7 M
Slightly volatile
Property Plant Equipment17.2 M16.3 M6.4 M
Slightly volatile
Common Stock Total Equity140.6 K156.8 K131.7 K
Slightly volatile
Capital Surpluse34.8 M42.1 M33.4 M
Slightly volatile
Non Current Liabilities Other788.3 K829.8 K6.7 M
Slightly volatile
Inventory562.3 K591.9 K1.6 M
Very volatile
Short and Long Term Debt2.5 M4.2 M2 M
Slightly volatile
Capital Stock157.2 K171 K142.9 K
Slightly volatile

CryoCell International Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization625.6 K556 K614.4 K
Slightly volatile
Selling General Administrative11.5 M21.3 M14.2 M
Slightly volatile
Total Revenue18.9 M36.8 M25.4 M
Slightly volatile
Gross Profit29 M27.6 M19.3 M
Slightly volatile
Other Operating Expenses18.4 M32.8 M23.1 M
Slightly volatile
Cost Of Revenue5.7 M9.1 M7 M
Slightly volatile
Total Operating Expenses12.9 M23.6 M16 M
Slightly volatile
Research Development1.5 M1.4 M453.9 K
Slightly volatile
Interest Expense1.2 M2.1 M1.4 M
Slightly volatile
Reconciled Depreciation1 M1.2 M709 K
Slightly volatile

CryoCell International Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation646 K1.2 M715.3 K
Slightly volatile
Other Non Cash Items455.6 K479.5 K2 M
Pretty Stable
Capital Expenditures1.8 M2.8 M2.6 M
Slightly volatile
Total Cash From Operating Activities7.3 M6.9 M5.4 M
Slightly volatile
End Period Cash Flow612.8 K645.1 K3.6 M
Pretty Stable
Begin Period Cash Flow443.6 K467 K3.9 M
Pretty Stable
Stock Based Compensation630.7 K898.3 K680 K
Very volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio2.412.532.4255
Pretty Stable
Dividend Yield0.02450.02580.1422
Slightly volatile
Days Sales Outstanding79.795.9275.1943
Slightly volatile
Operating Cash Flow Per Share0.70.670.6336
Slightly volatile
Average Payables2.3 M2.2 M1.5 M
Slightly volatile
Stock Based Compensation To Revenue0.02780.02810.0272
Pretty Stable
Capex To Depreciation1.412.122.18
Slightly volatile
EV To Sales2.832.982.5377
Pretty Stable
Inventory Turnover11.8713.910.2963
Slightly volatile
Days Of Inventory On Hand33.034.7476.5837
Very volatile
Payables Turnover6.444.864.9734
Slightly volatile
Sales General And Administrative To Revenue0.580.620.5765
Slightly volatile
Average Inventory885 K931.6 K2.1 M
Pretty Stable
Research And Ddevelopement To Revenue0.04240.04470.0435
Slightly volatile
Capex To Revenue0.150.08640.0936
Slightly volatile
Cash Per Share0.410.390.5379
Very volatile
POCF Ratio11.3210.5515.5587
Slightly volatile
Capex To Operating Cash Flow0.580.460.414
Slightly volatile
Days Payables Outstanding98.0499.4183.3889
Very volatile
EV To Operating Cash Flow15.0615.8516.2795
Slightly volatile
Intangibles To Total Assets0.03270.03980.0689
Pretty Stable
Current Ratio0.640.671.0099
Slightly volatile
Receivables Turnover7.465.035.1868
Pretty Stable
Capex Per Share0.150.270.3043
Slightly volatile
Average Receivables6 M5.7 M5 M
Slightly volatile
Revenue Per Share3.723.543.0524
Slightly volatile
Interest Debt Per Share1.992.091.1328
Slightly volatile
Debt To Assets0.220.230.2063
Very volatile
Graham Number0.921.551.6206
Very volatile
Operating Cycle86.26102138
Very volatile
Days Of Payables Outstanding98.0499.4183.3889
Very volatile
Price To Operating Cash Flows Ratio11.3210.5515.5587
Slightly volatile
Quick Ratio0.60.630.9142
Slightly volatile
Cash Ratio0.02840.02990.3754
Slightly volatile
Operating Cash Flow Sales Ratio0.180.170.2045
Pretty Stable
Days Of Inventory Outstanding33.034.7476.5837
Very volatile
Days Of Sales Outstanding79.795.9275.1943
Slightly volatile
Fixed Asset Turnover1.21.2711.6035
Slightly volatile
Price Cash Flow Ratio11.3210.5515.5587
Slightly volatile
Debt Ratio0.220.230.2063
Very volatile
Price Sales Ratio2.412.532.4255
Pretty Stable
Asset Turnover0.690.450.8671
Slightly volatile
Gross Profit Margin0.560.680.7194
Slightly volatile

CryoCell International Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap66.6 M63.4 M52.7 M
Slightly volatile
Enterprise Value90.5 M95.3 M58.6 M
Slightly volatile

CryoCell Fundamental Market Drivers

CryoCell Upcoming Events

27th of February 2024
Upcoming Quarterly Report
View
30th of November 2023
Next Fiscal Quarter End
View

About CryoCell International Financial Statements

CryoCell International investors utilize fundamental indicators, such as revenue or net income, to predict how CryoCell Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue11.3 M6.6 M
Total Revenue36.8 M18.9 M
Cost Of Revenue9.1 M5.7 M
Stock Based Compensation To Revenue 0.03  0.03 
Sales General And Administrative To Revenue 0.62  0.58 
Research And Ddevelopement To Revenue 0.04  0.04 
Capex To Revenue 0.09  0.15 
Revenue Per Share 3.54  3.72 
Ebit Per Revenue 0.10  0.10 

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether CryoCell International is a strong investment it is important to analyze CryoCell International's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact CryoCell International's future performance. For an informed investment choice regarding CryoCell Stock, refer to the following important reports:
How To Invest In CryoCell
Details
Is CryoCell Stock a good investment?
Details
What is CryoCell International's Net Worth?
Details
Largest Health Care Providers & Services Companies
View
Largest Health Care Equipment & Services Companies
View
Check out the analysis of CryoCell International Correlation against competitors.
For more information on how to buy CryoCell Stock please use our How to buy in CryoCell Stock guide.
You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CryoCell International. Projected growth potential of CryoCell fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive CryoCell International assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth
(0.31)
Dividend Share
0.65
Earnings Share
(0.06)
Revenue Per Share
3.933
Quarterly Revenue Growth
(0.03)
Investors evaluate CryoCell International using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating CryoCell International's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause CryoCell International's market price to deviate significantly from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
It's important to distinguish between CryoCell International's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding CryoCell International should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, CryoCell International's market price signifies the transaction level at which participants voluntarily complete trades.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY